Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer have?
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer has 2,070 citations in the OpenAlex counts ScholarIQ stores.
When was Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer published?
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer has 2019 year in the ScholarIQ index.
What is the open-access status of Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer?
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer?
The DOI for Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer is on the source record.
What is the PMID of Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer?
The PMID for Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer is on the source record.
What is the OpenAlex record for Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer?
The OpenAlex for Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer is on the source record.